• Consensus Rating: Moderate Buy
  • Consensus Price Target: $288.46
  • Forecasted Upside: 26.69%
  • Number of Analysts: 26
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 17 Buy Ratings
  • 0 Strong Buy Ratings
$227.69
▼ -3.89 (-1.68%)

This chart shows the closing price for BIIB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIIB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIIB

Analyst Price Target is $288.46
▲ +26.69% Upside Potential
This price target is based on 26 analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $288.46, with a high forecast of $373.00 and a low forecast of $200.00. The average price target represents a 26.69% upside from the last price of $227.69.

This chart shows the closing price for BIIB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 26 investment analysts is to moderate buy stock in Biogen. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 0 sell ratings
2/21/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 0 sell ratings
4/21/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 0 sell ratings
5/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2024Truist FinancialReiterated RatingBuy ➝ Buy$340.00 ➝ $340.00Low
5/3/2024HSBCBoost TargetBuy ➝ Buy$339.00 ➝ $342.00Low
4/29/2024OppenheimerReiterated RatingOutperform ➝ Outperform$270.00 ➝ $270.00Low
4/25/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$215.00 ➝ $200.00Low
4/25/2024WedbushBoost TargetNeutral ➝ Neutral$213.00 ➝ $215.00Low
4/25/2024HC WainwrightLower TargetBuy ➝ Buy$325.00 ➝ $300.00Low
4/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$294.00Low
4/19/2024OppenheimerLower TargetOutperform ➝ Outperform$290.00 ➝ $270.00Low
4/17/2024UBS GroupLower TargetNeutral ➝ Neutral$250.00 ➝ $214.00Low
4/17/2024WedbushLower TargetNeutral ➝ Neutral$245.00 ➝ $213.00N/A
4/12/2024Bank of AmericaLower TargetNeutral ➝ Neutral$280.00 ➝ $260.00Low
4/11/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$270.00 ➝ $240.00Low
4/4/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$230.00 ➝ $215.00Low
4/1/2024William BlairReiterated RatingOutperformLow
3/25/2024Truist FinancialReiterated RatingBuy ➝ Buy$340.00Low
3/5/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$364.00Low
2/22/2024MizuhoLower TargetBuy ➝ Buy$355.00 ➝ $277.00Low
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$311.00Low
2/20/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$310.00 ➝ $305.00Low
2/16/2024UBS GroupLower TargetNeutral ➝ Neutral$276.00 ➝ $250.00Low
2/14/2024Robert W. BairdLower TargetOutperform ➝ Outperform$333.00 ➝ $316.00Low
2/14/2024Piper SandlerLower TargetOverweight ➝ Overweight$350.00 ➝ $325.00Low
2/14/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$295.00 ➝ $285.00Low
2/14/2024OppenheimerLower TargetOutperform ➝ Outperform$295.00 ➝ $290.00Low
2/14/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$379.00 ➝ $364.00Low
2/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$325.00Low
2/14/2024Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$315.00 ➝ $240.00Low
2/13/2024Needham & Company LLCLower TargetBuy ➝ Buy$305.00 ➝ $300.00Low
2/12/2024Royal Bank of CanadaBoost TargetOverweight ➝ Overweight$363.00 ➝ $379.00Low
2/12/2024Bank Of America (Bofa)Lower TargetNeutral ➝ Neutral$290.00 ➝ $280.00Low
2/12/2024WedbushBoost TargetNeutral ➝ Neutral$239.00 ➝ $245.00Low
1/30/2024OppenheimerReiterated RatingOutperform ➝ Outperform$295.00Low
1/24/2024UBS GroupDowngradeBuy ➝ Neutral$311.00 ➝ $276.00Low
1/10/2024William BlairReiterated RatingOutperformLow
1/7/2024BTIG ResearchReiterated RatingNeutralLow
12/20/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$311.00Low
12/18/2023OppenheimerBoost TargetOutperform ➝ Outperform$280.00 ➝ $295.00Low
12/14/2023Stifel NicolausLower TargetBuy ➝ Buy$315.00 ➝ $287.00Low
12/7/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$283.00Low
11/10/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$361.00 ➝ $373.00Low
11/9/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$351.00 ➝ $363.00Low
11/9/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$314.00 ➝ $295.00Low
11/9/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$343.00 ➝ $365.00Low
11/9/2023WedbushLower TargetNeutral ➝ Neutral$266.00 ➝ $239.00Low
11/9/2023William BlairReiterated RatingOutperformLow
11/8/2023UBS GroupLower TargetBuy ➝ Buy$327.00 ➝ $312.00Low
10/26/2023William BlairReiterated RatingOutperformLow
10/26/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$305.00Low
10/26/2023WedbushLower TargetNeutral ➝ Neutral$270.00 ➝ $266.00Low
10/11/2023Morgan StanleyLower TargetOverweight ➝ Overweight$381.00 ➝ $361.00Low
9/6/2023HSBCInitiated CoverageBuy$360.00Low
9/5/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$363.00 ➝ $381.00Low
8/29/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$354.00 ➝ $357.00Low
8/14/2023MizuhoLower TargetBuy ➝ Buy$340.00 ➝ $335.00Low
8/8/2023Truist FinancialLower TargetBuy ➝ Buy$340.00Low
8/8/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$347.00 ➝ $336.00Low
8/8/2023Atlantic SecuritiesLower TargetNeutral ➝ Neutral$282.00 ➝ $275.00Low
8/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$323.00 ➝ $305.00Low
8/8/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$311.00 ➝ $294.00Low
8/7/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$374.00 ➝ $354.00Low
8/7/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$350.00 ➝ $343.00Low
8/7/2023Piper SandlerLower Target$380.00 ➝ $350.00Low
8/7/2023OppenheimerLower TargetOutperform ➝ Outperform$360.00 ➝ $290.00Low
8/7/2023Bank of AmericaLower Target$310.00 ➝ $290.00Low
8/7/2023WedbushLower Target$276.00 ➝ $269.00Low
8/7/2023Robert W. BairdLower Target$340.00 ➝ $333.00Low
7/31/2023Royal Bank of CanadaLower TargetOutperform$379.00 ➝ $374.00Low
7/27/2023ScotiabankInitiated CoverageSector Outperform$327.00Low
7/26/2023Royal Bank of CanadaBoost Target$341.00 ➝ $379.00Low
7/26/2023Needham & Company LLCBoost TargetBuy ➝ Buy$320.00 ➝ $323.00Low
7/26/2023Bank of AmericaLower Target$320.00 ➝ $310.00Low
7/26/2023BMO Capital MarketsLower TargetOutperform$357.00 ➝ $347.00Low
7/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$325.00Low
7/25/2023Stifel NicolausLower TargetBuy$324.00 ➝ $320.00Low
7/25/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$320.00Low
7/24/2023UBS GroupLower TargetBuy$346.00 ➝ $335.00Low
7/18/2023BMO Capital MarketsLower Target$380.00 ➝ $357.00Low
7/11/2023Royal Bank of CanadaBoost Target$332.00 ➝ $341.00Low
6/12/2023OppenheimerBoost Target$350.00 ➝ $360.00Low
6/1/2023Piper SandlerBoost Target$346.00 ➝ $360.00Low
5/11/2023ArgusBoost Target$320.00 ➝ $350.00Low
5/4/2023Bank of AmericaBoost Target$300.00 ➝ $320.00Low
5/3/2023MizuhoBoost Target$315.00 ➝ $340.00Low
5/1/2023GuggenheimUpgradeNeutral ➝ Buy$270.00 ➝ $350.00Low
4/26/2023Royal Bank of CanadaLower Target$344.00 ➝ $340.00Low
4/26/2023Needham & Company LLCLower Target$325.00 ➝ $321.00Low
4/26/2023UBS GroupLower Target$347.00 ➝ $346.00Low
4/26/2023OppenheimerBoost Target$310.00 ➝ $325.00Low
4/26/2023BarclaysLower Target$307.00 ➝ $302.00Low
4/25/2023Morgan StanleyBoost Target$349.00 ➝ $371.00Low
4/21/2023Bank of AmericaBoost TargetNeutral$295.00 ➝ $300.00Low
4/17/2023WedbushBoost TargetNeutral$249.00 ➝ $263.00Low
4/17/2023ArgusBoost TargetBuy$315.00 ➝ $320.00Low
4/17/2023Piper SandlerUpgradeNeutral ➝ Overweight$280.00 ➝ $346.00Low
4/12/2023Morgan StanleyLower TargetOverweight$351.00 ➝ $349.00Low
4/12/2023BarclaysLower Target$310.00 ➝ $307.00Low
4/11/2023Needham & Company LLCReiterated RatingBuy$325.00Low
3/23/2023HC WainwrightReiterated RatingBuy$325.00Low
3/13/2023Royal Bank of CanadaBoost Target$335.00 ➝ $350.00Low
2/16/2023UBS GroupBoost TargetBuy$337.00 ➝ $340.00Low
2/16/2023HC WainwrightReiterated RatingBuy$325.00Low
2/16/2023Royal Bank of CanadaLower TargetOutperform$359.00 ➝ $333.00Low
2/16/2023CowenBoost TargetOutperform$300.00 ➝ $315.00Low
2/16/2023Morgan StanleyBoost TargetOverweight$345.00 ➝ $351.00Low
2/16/2023OppenheimerLower TargetOutperform$320.00 ➝ $310.00Low
2/15/2023Needham & Company LLCReiterated RatingBuy$325.00Low
1/25/2023Needham & Company LLCReiterated RatingBuy$325.00Low
1/24/2023Morgan StanleyBoost TargetOverweight$325.00 ➝ $345.00Low
12/1/2022The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$370.00Low
12/1/2022Atlantic SecuritiesBoost TargetNeutral$220.00 ➝ $295.00Low
11/30/2022MizuhoInitiated CoverageBuy$325.00Low
11/30/2022Jefferies Financial GroupBoost TargetBuy$325.00 ➝ $350.00Low
11/30/2022WedbushBoost TargetNeutral$218.00 ➝ $247.00Low
11/30/2022BarclaysBoost TargetEqual Weight$275.00 ➝ $313.00Low
11/15/2022Truist FinancialBoost TargetBuy$265.00 ➝ $350.00Low
11/14/2022OppenheimerBoost TargetOutperform$300.00 ➝ $315.00Low
11/11/2022GuggenheimBoost TargetNeutral$265.00 ➝ $270.00Low
11/1/2022MizuhoBoost TargetBuy$270.00 ➝ $325.00Low
10/28/2022OppenheimerReiterated RatingOutperform ➝ Outperform$300.00Low
10/26/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$285.00 ➝ $325.00Low
10/26/2022CowenBoost Target$270.00 ➝ $300.00Low
10/26/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$220.00 ➝ $370.00Low
10/26/2022Morgan StanleyBoost TargetOverweight$321.00 ➝ $325.00Low
10/26/2022CowenBoost Target$270.00 ➝ $300.00Low
10/26/2022Royal Bank of CanadaBoost TargetOutperform$310.00 ➝ $331.00Low
10/26/2022HC WainwrightBoost TargetBuy$240.00 ➝ $325.00Low
10/26/2022Atlantic SecuritiesBoost TargetNeutral$200.00 ➝ $220.00Low
10/26/2022SVB LeerinkBoost TargetOutperform$270.00 ➝ $310.00Low
10/24/2022Jefferies Financial GroupBoost TargetBuy$300.00 ➝ $325.00Low
10/13/2022Morgan StanleyBoost TargetOverweight$285.00 ➝ $321.00Low
10/12/2022Stifel NicolausUpgradeHold ➝ Buy$223.00 ➝ $299.00Low
10/7/2022ArgusUpgradeHold ➝ Buy$300.00Low
10/7/2022BarclaysBoost TargetEqual Weight$200.00 ➝ $275.00Low
10/6/2022UBS GroupBoost TargetBuy$238.00 ➝ $309.00Low
9/30/2022JPMorgan Chase & Co.Boost TargetNeutral$221.00 ➝ $275.00Low
9/29/2022OppenheimerBoost Target$230.00 ➝ $300.00Low
9/28/2022Piper SandlerBoost TargetNeutral$200.00 ➝ $280.00Low
9/28/2022Royal Bank of CanadaBoost Target$251.00 ➝ $321.00Low
9/28/2022Wells Fargo & CompanyBoost TargetOverweight$265.00 ➝ $350.00Low
9/28/2022WedbushBoost TargetNeutral$183.00 ➝ $217.00Low
9/28/2022Robert W. BairdUpgradeNeutral ➝ Outperform$224.00 ➝ $340.00Low
9/28/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$217.00 ➝ $360.00Low
9/28/2022MizuhoUpgradeNeutral ➝ Buy$207.00 ➝ $270.00Low
9/22/2022Truist FinancialLower TargetBuy$270.00 ➝ $265.00Low
9/20/2022Jefferies Financial GroupReiterated RatingBuy ➝ Buy$300.00Low
9/12/2022Stifel NicolausLower TargetHold$230.00 ➝ $223.00Low
8/2/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$224.00Low
7/22/2022UBS GroupLower Target$238.00Low
7/22/2022GuggenheimLower Target$190.00Low
7/22/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$224.00Low
7/21/2022CowenLower TargetOutperform$285.00 ➝ $270.00Low
7/21/2022Truist FinancialLower TargetBuy$320.00 ➝ $270.00Low
7/21/2022Needham & Company LLCLower TargetBuy$262.00 ➝ $250.00Low
7/21/2022CowenLower Target$285.00 ➝ $270.00Low
7/21/2022BarclaysLower TargetEqual Weight$210.00 ➝ $200.00Low
7/20/2022Royal Bank of CanadaLower Target$264.00 ➝ $259.00Low
7/18/2022OppenheimerBoost TargetOutperform$225.00 ➝ $230.00Low
5/4/2022OppenheimerLower Target$240.00 ➝ $225.00Medium
5/4/2022BarclaysLower Target$219.00 ➝ $210.00Medium
4/28/2022WedbushReiterated RatingNeutralMedium
4/21/2022SVB LeerinkLower TargetOutperform$300.00 ➝ $270.00Medium
4/18/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$235.00 ➝ $265.00Medium
4/12/2022Morgan StanleyLower TargetOverweight$330.00 ➝ $283.00High
4/12/2022BarclaysLower TargetEqual Weight$235.00 ➝ $219.00Medium
4/8/2022Needham & Company LLCLower TargetBuy$290.00 ➝ $262.00High
4/8/2022OppenheimerLower TargetOutperform$285.00 ➝ $240.00High
3/28/2022Bank of AmericaLower TargetNeutral$230.00 ➝ $225.00Low
3/25/2022OppenheimerReiterated RatingOutperform ➝ Outperform$285.00Low
3/8/2022Stifel NicolausDowngradeBuy ➝ Hold$304.00 ➝ $223.00Medium
3/3/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$227.00 ➝ $248.00Low
2/7/2022Canaccord Genuity GroupLower TargetBuy$335.00 ➝ $305.00Low
2/4/2022CowenLower TargetOutperform$375.00 ➝ $285.00High
2/4/2022Wolfe ResearchLower TargetPeer Perform$244.00 ➝ $217.00High
2/4/2022Bank of AmericaLower TargetNeutral$245.00 ➝ $230.00High
2/4/2022Needham & Company LLCLower TargetBuy$292.00 ➝ $290.00High
2/4/2022Royal Bank of CanadaBoost TargetSector Perform$225.00 ➝ $227.00High
2/4/2022WedbushLower TargetNeutral$195.00 ➝ $185.00High
2/4/2022Wells Fargo & CompanyLower TargetEqual Weight$284.00 ➝ $235.00High
2/4/2022Morgan StanleyLower TargetOverweight$360.00 ➝ $330.00High
2/4/2022OppenheimerLower TargetOutperform$350.00 ➝ $285.00High
2/4/2022BarclaysLower TargetEqual Weight$244.00 ➝ $235.00High
2/4/2022Robert W. BairdLower TargetNeutral$258.00 ➝ $224.00High
2/4/2022BMO Capital MarketsDowngradeOutperform ➝ Market Perform$260.00 ➝ $238.00Medium
2/3/2022Stifel NicolausLower Target$344.00 ➝ $304.00Low
1/24/2022SVB LeerinkLower TargetOutperform$325.00 ➝ $300.00High
1/20/2022BarclaysLower TargetEqual Weight$280.00 ➝ $244.00Medium
1/18/2022Morgan StanleyLower TargetOverweight$363.00 ➝ $360.00Low
1/18/2022HC WainwrightLower TargetBuy$452.00 ➝ $270.00Low
1/14/2022Bank of AmericaLower TargetNeutral ➝ Neutral$275.00 ➝ $245.00Low
1/13/2022GuggenheimDowngradeBuy ➝ Neutral$290.00 ➝ $202.00High
1/12/2022MizuhoLower TargetNeutral$270.00 ➝ $207.00High
1/12/2022WedbushLower TargetNeutral$249.00 ➝ $195.00High
1/12/2022Piper SandlerDowngradeOverweight ➝ Neutral$362.00 ➝ $216.00High
1/11/2022Needham & Company LLCLower TargetBuy$386.00 ➝ $328.00High
1/10/2022Truist FinancialLower TargetBuy ➝ Buy$502.00 ➝ $343.00High
1/6/2022Morgan StanleyLower TargetOverweight$440.00 ➝ $363.00Low
1/3/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$258.00Low
1/3/2022UBS GroupLower Target$390.00 ➝ $335.00Low
12/30/2021Wells Fargo & CompanyBoost Target$250.00 ➝ $284.00Low
12/23/2021Bank of AmericaLower TargetNeutral$295.00 ➝ $275.00Low
12/22/2021Truist FinancialLower TargetReduce ➝ Buy$502.00Low
12/22/2021OppenheimerLower TargetOutperform$390.00 ➝ $350.00Low
12/21/2021JPMorgan Chase & Co.Lower TargetNeutral$324.00 ➝ $276.00Low
12/21/2021Robert W. BairdLower TargetNeutral$296.00 ➝ $258.00Medium
12/20/2021SVB LeerinkLower TargetOutperform$450.00 ➝ $325.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$250.00Low
12/6/2021The Goldman Sachs GroupInitiated CoverageNeutral$271.00Low
11/19/2021Royal Bank of CanadaLower TargetSector Perform$295.00 ➝ $277.00Low
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$315.00Low
10/28/2021Cantor FitzgeraldLower TargetNeutral$316.00 ➝ $259.00Medium
10/26/2021MizuhoLower TargetNeutral$300.00 ➝ $270.00Low
10/21/2021HC WainwrightReiterated RatingBuy$453.00Low
10/21/2021Truist FinancialLower TargetBuy$647.00 ➝ $502.00Low
10/21/2021Morgan StanleyLower TargetOverweight$447.00 ➝ $440.00Medium
10/21/2021CowenBoost TargetOutperform$375.00 ➝ $450.00Medium
10/21/2021OppenheimerDowngradeOverweight$450.00 ➝ $390.00Medium
10/21/2021Royal Bank of CanadaLower TargetSector Perform$325.00 ➝ $295.00Medium
10/20/2021Piper SandlerLower TargetOverweight$460.00 ➝ $390.00Medium
10/19/2021Needham & Company LLCInitiated CoverageBuy$400.00 ➝ $399.00High
10/18/2021Jefferies Financial GroupReiterated RatingBuyHigh
10/15/2021Stifel NicolausLower TargetBuy$430.00 ➝ $344.00Low
10/15/2021Cantor FitzgeraldLower TargetNeutral$427.00 ➝ $327.00High
10/12/2021Morgan StanleyLower TargetOverweight$455.00 ➝ $447.00Low
10/8/2021Jefferies Financial GroupLower TargetBuy$500.00 ➝ $400.00Low
10/8/2021BarclaysLower TargetEqual Weight$395.00 ➝ $290.00Low
10/5/2021HC WainwrightReiterated RatingBuy$452.00Medium
10/5/2021SVB LeerinkReiterated RatingBuyLow
9/29/2021Royal Bank of CanadaLower TargetSector Perform$341.00 ➝ $326.00Low
9/24/2021Robert W. BairdInitiated CoverageHold$296.00Low
9/23/2021MizuhoInitiated CoverageHold$300.00Low
9/23/2021HC WainwrightReiterated RatingBuy$452.00Low
9/22/2021Needham & Company LLCInitiated CoverageBuy$400.00Low
9/16/2021UBS GroupBoost TargetPositive ➝ Buy$442.00 ➝ $475.00Low
9/15/2021Bank of AmericaLower TargetNeutral$400.00 ➝ $360.00Low
8/2/2021MizuhoBoost TargetNeutral$244.00 ➝ $300.00Medium
7/27/2021Cantor FitzgeraldReiterated RatingNeutral$435.00 ➝ $327.51Low
7/23/2021Morgan StanleyBoost TargetOverweight$453.00 ➝ $455.00Low
7/23/2021Royal Bank of CanadaLower TargetSector Perform$361.00 ➝ $341.00Low
7/22/2021Stifel NicolausLower TargetAverage ➝ Buy$443.00 ➝ $430.00Low
7/19/2021Evercore ISISet TargetBuy$324.62Low
7/16/2021Morgan StanleyLower TargetOverweight$455.00 ➝ $453.00Low
7/11/2021Robert W. BairdSet TargetHold$358.16Medium
6/28/2021Royal Bank of CanadaLower TargetSector Perform$400.00 ➝ $354.00Low
6/18/2021Piper SandlerUpgradeNeutral ➝ Overweight$384.00 ➝ $450.00Low
6/15/2021Bank of AmericaReiterated RatingBuy$415.00Low
6/14/2021The Goldman Sachs GroupBoost TargetAverage ➝ Neutral$246.00 ➝ $436.00Low
6/11/2021Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$500.00Medium
6/10/2021UBS GroupUpgradeNeutral ➝ Buy$463.00Low
6/10/2021SVB LeerinkBoost TargetOutperform$380.00 ➝ $475.00Medium
6/8/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
6/8/2021Royal Bank of CanadaBoost TargetSector Perform$259.00 ➝ $400.00High
6/8/2021Jefferies Financial GroupBoost TargetBuy$450.00 ➝ $500.00Medium
6/8/2021Morgan StanleyBoost TargetOverweight$343.00 ➝ $455.00Medium
6/8/2021BarclaysBoost TargetEqual Weight$265.00 ➝ $395.00Medium
6/8/2021HC WainwrightBoost TargetBuy$305.00 ➝ $452.00Medium
6/8/2021CitigroupUpgradeSell ➝ NeutralMedium
6/8/2021Atlantic SecuritiesUpgradeUnderweight ➝ Neutral$415.00Low
6/7/2021Robert W. BairdUpgradeUnderperform ➝ Neutral$216.00 ➝ $382.00Medium
6/7/2021Raymond JamesUpgradeUnderperform ➝ Market PerformMedium
6/7/2021CowenUpgradeMarket Perform ➝ Outperform$225.00 ➝ $450.00High
6/7/2021Bank of AmericaUpgradeUnderperform ➝ Neutral$235.00 ➝ $400.00High
5/18/2021OppenheimerBoost TargetOutperform$300.00 ➝ $325.00Low
4/23/2021HC WainwrightReiterated RatingBuyLow
4/19/2021Morgan StanleyLower TargetOverweight$351.00 ➝ $343.00Low
4/12/2021WedbushBoost TargetNeutral$236.00 ➝ $245.00Medium
2/17/2021Cantor FitzgeraldLower TargetNeutral$278.00 ➝ $268.00Low
2/5/2021DZ BankDowngradeBuy ➝ Hold$264.00Low
2/4/2021Credit Suisse GroupLower TargetOutperform$388.00 ➝ $350.00Medium
2/4/2021SVB LeerinkLower TargetPositive ➝ Outperform$430.00 ➝ $380.00Medium
2/4/2021Morgan StanleyLower TargetOverweight$352.00 ➝ $351.00Medium
2/4/2021HC WainwrightBoost TargetBuy$289.00 ➝ $305.00Medium
2/3/2021Piper SandlerLower TargetNeutral$265.00 ➝ $250.00Low
1/29/2021Stifel NicolausUpgradeHold ➝ Buy$258.00 ➝ $358.00High
1/19/2021Morgan StanleyLower TargetOverweight$357.00 ➝ $352.00High
12/1/2020William BlairReiterated RatingMarket PerformLow
12/1/2020Royal Bank of CanadaBoost TargetReduce ➝ Sector Perform$249.00 ➝ $256.00Low
11/19/2020Royal Bank of CanadaBoost TargetSector Perform$244.00 ➝ $249.00Low
11/10/2020Truist FinancialDowngradeBuy$310.00 ➝ $443.00Low
11/10/2020DZ BankUpgradeHold ➝ Buy$265.00Low
11/9/2020Royal Bank of CanadaLower TargetSector Perform$263.00 ➝ $244.00High
11/9/2020OppenheimerLower TargetOutperform$370.00 ➝ $330.00Medium
11/9/2020MizuhoLower TargetNeutral$282.00 ➝ $244.00Medium
11/9/2020HC WainwrightLower TargetBuy$318.00 ➝ $289.00High
11/9/2020CowenDowngradeOutperform ➝ Market Perform$275.00 ➝ $215.00High
11/9/2020Bank of AmericaDowngradeNeutral ➝ Underperform$240.00High
11/9/2020Atlantic SecuritiesDowngradeNeutral ➝ Underweight$175.00High
11/5/2020SVB LeerinkBoost TargetPositive ➝ Outperform$342.00 ➝ $402.00High
11/5/2020BMO Capital MarketsUpgradeMarket Perform$280.00 ➝ $343.00High
11/4/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$230.00 ➝ $360.00High
11/4/2020Jefferies Financial GroupUpgradeHold ➝ Buy$450.00High
11/4/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$437.00 ➝ $390.00High
11/3/2020Cantor FitzgeraldLower Target$339.00 ➝ $278.00Low
10/28/2020UBS GroupInitiated CoverageNeutral$268.00High
10/27/2020MizuhoLower TargetNeutral$316.00 ➝ $282.00Low
10/22/2020HC WainwrightReiterated RatingBuyLow
10/22/2020OppenheimerLower TargetOutperform$360.00 ➝ $340.00Low
10/22/2020BarclaysLower TargetEqual Weight$275.00 ➝ $265.00Low
10/22/2020WedbushLower TargetNeutral$281.00 ➝ $244.00Low
10/22/2020Credit Suisse GroupLower TargetOutperform$359.00 ➝ $350.00Low
10/22/2020Morgan StanleyBoost TargetOverweight$355.00 ➝ $357.00Low
10/20/2020Piper SandlerLower TargetNeutral$270.00 ➝ $265.00Low
10/19/2020Royal Bank of CanadaLower TargetSector Perform$281.00 ➝ $268.00High
10/15/2020Bank of AmericaLower TargetUnderperform$255.00 ➝ $235.00Low
10/13/2020Morgan StanleyLower TargetOverweight$357.00 ➝ $355.00Low
9/18/2020Royal Bank of CanadaLower TargetSector Perform$284.00 ➝ $277.00High
9/13/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
8/19/2020SVB LeerinkLower TargetOutperform$350.00 ➝ $342.00Medium
8/7/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform$270.00 ➝ $375.00Medium
8/7/2020OppenheimerBoost TargetOutperform$325.00 ➝ $360.00High
7/31/2020Raymond JamesReiterated RatingSellLow
7/29/2020JPMorgan Chase & Co.Reiterated RatingHold$279.00Low
7/27/2020Morgan StanleyUpgradeUnderweight ➝ Overweight$263.00 ➝ $357.00High
7/23/2020BMO Capital MarketsLower TargetMarket Perform$317.00 ➝ $280.00Low
7/22/2020MizuhoReiterated RatingHold$316.00Low
7/22/2020Wells Fargo & CompanyBoost TargetEqual Weight$311.00 ➝ $324.00Low
7/22/2020Stifel NicolausLower TargetPositive ➝ Hold$294.00 ➝ $284.00Medium
7/16/2020OppenheimerReiterated RatingBuy$325.00Low
7/15/2020Morgan StanleyLower TargetUnderweight$301.00 ➝ $263.00Low
7/13/2020The Goldman Sachs GroupLower TargetNeutral$300.00 ➝ $257.00Medium
7/10/2020William BlairReiterated RatingHoldLow
7/8/2020SunTrust BanksReiterated RatingBuy$330.00Low
7/8/2020GuggenheimReiterated RatingBuy$390.00Low
7/6/2020Royal Bank of CanadaReiterated RatingHold$276.00Low
6/25/2020Credit Suisse GroupReiterated RatingHold$270.00Low
6/22/2020Royal Bank of CanadaLower TargetSector Perform$303.00 ➝ $273.00Low
6/22/2020BarclaysDowngradeOverweight ➝ Equal Weight$370.00 ➝ $280.00Low
6/19/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
6/19/2020William BlairReiterated RatingHoldHigh
6/19/2020Robert W. BairdLower TargetUnderperform$290.00 ➝ $228.00High
6/19/2020Credit Suisse GroupLower TargetNeutral$310.00 ➝ $270.00High
6/19/2020Piper SandlerLower TargetNeutral$307.00 ➝ $260.00High
6/18/2020MizuhoReiterated RatingHold$316.00High
6/9/2020Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$360.00 ➝ $297.00Medium
5/28/2020Morgan StanleyReiterated RatingSell$301.00Low
5/1/2020Cantor FitzgeraldReiterated RatingNeutral$361.00 ➝ $308.00Low
4/30/2020Royal Bank of CanadaReiterated RatingHold$310.00High
4/24/2020William BlairReiterated RatingHoldHigh
4/23/2020Morgan StanleyLower TargetUnderweight$302.00 ➝ $301.00Medium
4/23/2020SunTrust BanksLower TargetBuy$360.00 ➝ $330.00Medium
4/23/2020OppenheimerLower TargetOutperform$390.00 ➝ $365.00Low
4/23/2020Credit Suisse GroupLower TargetNeutral$344.00 ➝ $310.00Low
4/23/2020BarclaysLower TargetOverweight$389.00 ➝ $370.00Low
4/23/2020Royal Bank of CanadaLower TargetSector Perform$325.00 ➝ $310.00Low
4/23/2020CitigroupDowngradeNeutral ➝ Sell$365.00 ➝ $240.00Low
4/22/2020Raymond JamesDowngradeMarket Perform ➝ UnderperformMedium
4/22/2020Stifel NicolausLower TargetHold$296.00 ➝ $294.00High
4/22/2020WedbushLower TargetNeutral$306.00 ➝ $295.00High
4/22/2020MizuhoReiterated RatingHold$316.00High
4/8/2020SVB LeerinkReiterated RatingOutperformHigh
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$331.00Low
3/18/2020Royal Bank of CanadaReiterated RatingHold$335.00High
2/27/2020BarclaysInitiated CoverageOverweight$389.00High
2/25/2020MizuhoBoost TargetNeutral$300.00 ➝ $316.00Medium
2/11/2020William BlairReiterated RatingMarket PerformLow
2/7/2020OppenheimerBoost Target$338.00 ➝ $390.00Low
2/7/2020Nomura SecuritiesBoost TargetBuy$320.00 ➝ $392.00Low
2/6/2020BMO Capital MarketsReiterated RatingMarket Perform$317.00Low
2/6/2020Morgan StanleyBoost TargetUnderweight$261.00 ➝ $302.00Low
2/6/2020SVB LeerinkBoost TargetOutperform ➝ Positive$350.00 ➝ $410.00Medium
2/6/2020Credit Suisse GroupBoost TargetNeutral$300.00 ➝ $330.00Medium
2/6/2020Wells Fargo & CompanyBoost TargetEqual Weight$286.00 ➝ $311.00Low
2/6/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
2/6/2020HC WainwrightReiterated RatingBuy$335.00Medium
2/6/2020Cantor FitzgeraldBoost TargetNeutral$315.00 ➝ $361.00Medium
2/5/2020MizuhoReiterated RatingHold$300.00Low
2/5/2020Robert W. BairdBoost TargetUnderperform ➝ Underperform$250.00 ➝ $290.00Low
2/3/2020SVB LeerinkBoost TargetOutperform$350.00 ➝ $410.00High
2/3/2020SunTrust BanksBoost TargetBuy$337.00 ➝ $360.00Medium
2/2/2020Credit Suisse GroupReiterated RatingOverweight ➝ Hold$330.00 ➝ $300.00Low
1/31/2020Morgan StanleyLower TargetUnderweight$270.00 ➝ $261.00Low
1/31/2020Cantor FitzgeraldBoost TargetPositive ➝ Neutral$300.00 ➝ $315.00High
1/30/2020WedbushReiterated RatingNeutralHigh
1/30/2020JPMorgan Chase & Co.Reiterated RatingHoldLow
1/27/2020Royal Bank of CanadaReiterated RatingHold$285.00Low
1/23/2020Credit Suisse GroupReiterated RatingHold$300.00Low
1/23/2020Robert W. BairdReiterated RatingSell$250.00Low
1/17/2020Morgan StanleyBoost TargetUnderweight$262.00 ➝ $270.00Low
1/2/2020CowenReiterated RatingBuy$325.00Low
12/13/2019Credit Suisse GroupUpgradeUnderperform ➝ Neutral$260.00 ➝ $300.00Medium
12/6/2019Raymond JamesReiterated RatingHoldLow
12/6/2019HC WainwrightReiterated RatingBuy$335.00Low
12/2/2019Robert W. BairdDowngradeNeutral ➝ Underperform$250.00Low
11/18/2019Royal Bank of CanadaReiterated RatingHold$267.00Medium
11/12/2019SunTrust BanksInitiated CoverageBuy$337.00Medium
11/1/2019Standpoint ResearchDowngradeBuy ➝ HoldLow
10/29/2019Sanford C. BernsteinUpgradeMarket Perform ➝ OutperformLow
10/25/2019William BlairReiterated RatingHoldLow
10/23/2019Bank of AmericaBoost TargetUnderperform$200.00 ➝ $235.00Low
10/23/2019Credit Suisse GroupBoost TargetUnderperform$203.00 ➝ $260.00Low
10/23/2019JPMorgan Chase & Co.Boost TargetNeutral$244.00 ➝ $260.00Low
10/23/2019BMO Capital MarketsBoost TargetMarket Perform$250.00 ➝ $297.00Medium
10/23/2019CowenBoost TargetOutperform$275.00 ➝ $325.00High
10/23/2019Morgan StanleyBoost TargetUnderweight$212.00 ➝ $262.00High
10/23/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$256.00 ➝ $350.00High
10/23/2019HC WainwrightBoost TargetBuy$300.00 ➝ $335.00High
10/23/2019GuggenheimUpgradeNeutral ➝ Buy$256.00 ➝ $365.00Medium
10/22/2019Jefferies Financial GroupBoost TargetHold$255.00 ➝ $310.00High
10/22/2019Stifel NicolausBoost TargetPositive ➝ Hold$236.00 ➝ $296.00High
10/22/2019UBS GroupBoost TargetOutperform ➝ Positive$280.00 ➝ $334.00High
10/22/2019CowenReiterated RatingOutperform$275.00 ➝ $325.00High
10/22/2019MizuhoReiterated RatingHold$235.00High
10/16/2019Bank of AmericaInitiated CoverageUnderperform$200.00Low
10/15/2019OppenheimerSet TargetBuy$280.00Low
10/11/2019Morgan StanleyBoost TargetUnderweight$211.00 ➝ $212.00Medium
9/23/2019JPMorgan Chase & Co.Set TargetHold$244.00Low
9/6/2019Royal Bank of CanadaSet TargetHold$242.00High
7/30/2019CowenReiterated RatingBuy$275.00Low
7/26/2019Piper Sandler CompaniesReiterated RatingHoldN/A
7/25/2019MizuhoReiterated RatingHoldLow
6/28/2019Piper Sandler CompaniesDowngradeOverweight ➝ Neutral$280.00 ➝ $250.00Medium
6/5/2019Standpoint ResearchUpgradeHold ➝ BuyLow
5/23/2019CitigroupReiterated RatingNeutral ➝ NeutralMedium
5/22/2019WedbushInitiated CoverageNeutral ➝ Neutral$231.00High
(Data available from 5/22/2019 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 28 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
10/24/2023
  • 16 very positive mentions
  • 39 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
11/23/2023
  • 27 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/23/2023
  • 17 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 48 very positive mentions
  • 55 positive mentions
  • 21 negative mentions
  • 5 very negative mentions
2/21/2024
  • 38 very positive mentions
  • 38 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/22/2024
  • 21 very positive mentions
  • 24 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
4/21/2024
  • 49 very positive mentions
  • 48 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
5/21/2024

Current Sentiment

  • 49 very positive mentions
  • 48 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Biogen logo
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $227.69
Low: $224.82
High: $231.95

50 Day Range

MA: $212.97
Low: $190.52
High: $235.32

52 Week Range

Now: $227.69
Low: $189.44
High: $319.76

Volume

761,220 shs

Average Volume

1,290,178 shs

Market Capitalization

$33.15 billion

P/E Ratio

28.43

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Biogen?

The following Wall Street analysts have issued reports on Biogen in the last twelve months: Atlantic Securities, Bank Of America (Bofa), Bank of America Co., Barclays PLC, BMO Capital Markets, BTIG Research, Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, HSBC Holdings plc, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, StockNews.com, Truist Financial Co., UBS Group AG, Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for BIIB.

What is the current price target for Biogen?

24 Wall Street analysts have set twelve-month price targets for Biogen in the last year. Their average twelve-month price target is $288.46, suggesting a possible upside of 26.7%. Morgan Stanley has the highest price target set, predicting BIIB will reach $373.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $200.00 for Biogen in the next year.
View the latest price targets for BIIB.

What is the current consensus analyst rating for Biogen?

Biogen currently has 9 hold ratings and 17 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BIIB.

What other companies compete with Biogen?

How do I contact Biogen's investor relations team?

Biogen's physical mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (617) 679-2000 and its investor relations email address is [email protected]. The official website for Biogen is www.biogen.com. Learn More about contacing Biogen investor relations.